Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

Learn More
Banner

Antibody Drug Conjugate (ADC) Development for Pancreatic Cancer

Antibody Drug Conjugate (ADC) Development for Pancreatic Cancer

Antibody drug conjugates (ADCs) are a uniquely targeted cancer therapy that combines the direct tumor targeting capability of monoclonal antibodies together with the potency of cytotoxic drugs. Alfa Cytology offers cutting-edge services in the development of ADCs for pancreatic cancer, with a focus on providing innovative preclinical research solutions.

Advantages of Antibody Drug Conjugates (ADCs)

ADC selectively binds to cancer cell antigens, chemically linking the antibody to the cytotoxic drug through a stable junction that combines the specificity of a monoclonal antibody with the potent cell-killing ability of a cytotoxic drug, which enables tumor-specific delivery of potent cytotoxicity, while decreasing the extra-tumor toxicity associated with traditional cytotoxic chemotherapy, thereby increasing the therapeutic window.

Fig. 1 Structure of ADCs and specific components of ADCs.Fig. 1 Structure of ADCs and specific components of ADCs in development for targeting pancreatic cancer. (Wittwer, N.L, et al, 2023)

Components of Antibody Drug Conjugate (ADC)

Each component of the ADC can be customized to meet a range of pharmacological and clinical requirements. An ADC consists of three distinct parts:

  • A tumor-targeting monoclonal antibody (mAb) that specifically binds to a tumor-associated antigen
  • A highly potent cytotoxic drug (known as a payload)
  • A chemical linker

Key ADC Candidates in Development for Pancreatic Cancer

Antibody Drug Conjugate Cytotoxic Drug Target Phase
Trastuzumab Deruxtecan Deruxtecan (a topoisomerase I inhibitor) HER2 (Human Epidermal Growth Factor Receptor 2) Phase III
Mirvetuximab Soravtansine DM4 (a maytansinoid) FRα (Folate Receptor Alpha) Phase II
Enfortumab Vedotin MMAE (Monomethyl Auristatin E) Nectin-4 Phase III
AZD-9150 Monomethyl Auristatin E (MMAE) CD-70 (Cluster of Differentiation 70) Phase II
XmAb®20717 PBD (Pyrrolobenzodiazepine) dimer B7-H3 Phase I
Depatuxizumab Mafodotin MMAF (Monomethyl Auristatin F) EGFR (Epidermal Growth Factor Receptor) Phase I
Enapotamab Vedotin MMAE (Monomethyl Auristatin E) AXL receptor tyrosine kinase Phase I
DMUC5754A MMAE (Monomethyl Auristatin E) MUC16 (Mucin 16) Phase I

Our Services

By leveraging extensive expertise in basic pancreatic cancer research, Alfa Cytology ensures the highest quality and efficiency in ADC development, facilitating the advancement of promising therapeutic candidates from early-stage research to preclinical validation.

Target Antigen of ADC Development

Our ADC development service targets several key antigens associated with pancreatic cancer. These targets are chosen based on their high expression in tumor tissues and low expression in normal tissues, ensuring specificity and minimizing off-target effects. Key targets include:

  • EGFR
  • CEA
  • Tissue factor
  • CD70
  • ICAM1
  • Glypican-1
  • DR5
  • Mesothelin
  • Trop2
  • HER3
  • MUC1
  • CD71
  • SLC44A4

Antibody Drug Conjugate (ADC) Types We Offer

Monoclonal ADC

Utilize highly specific monoclonal antibodies for precise targeting of PC antigens.

Features: High specificity and minimal off-target effects, enhanced targeting accuracy and reduced systemic toxicity.

Bispecific ADC (BsADCs)

Employ bispecific antibodies that target two different antigens on pancreatic cancer cells.

Features: Dual targeting capability, improved tumor specificity and reduced likelihood of resistance.

Single-domain ADC

Involve single-domain antibodies (VHHs) for targeting pancreatic cancer antigens.

Features: Small size, deep tissue penetration, better tumor penetration and faster clearance from non-target tissues.

Antibody Fragment-drug Conjugates (FDCs)

Conjugate cytotoxic drugs to antibody fragments, such as Fab or scFv, for PC therapy.

Features: Smaller molecule size, better tumor penetration, improved pharmacokinetics and reduced immunogenicity.

Workflow of Antibody Drug Conjugate (ADC) Development

Our development process for ADCs follows a meticulous and systematic approach to ensure the highest standards of efficacy and safety. The process includes the following steps:

Target Identification

Comprehensive analysis to identify and validate appropriate targets specific to pancreatic cancer cells.

Antibody Generation

Development and selection of high-affinity antibodies against the identified targets.

Conjugation Chemistry

Optimization of linker and drug conjugation methods to ensure stable and effective ADCs.

In vitro Testing

Extensive in vitro assays to evaluate the binding specificity, cytotoxicity, and mechanism of action of the ADCs.

In vivo Testing

Preclinical animal studies to assess the efficacy, pharmacokinetics, and safety profile of the ADCs.

Why Choose Us?

Tailored Solutions

Advanced Technology

Professional Expertise

Collaborative Approach

Antibody-drug conjugates represent a revolutionary advancement in targeted cancer therapy, combining the specificity of antibodies with the potent cytotoxic effects of chemotherapy agents. Alfa Cytology's ADC development services for pancreatic cancer provide comprehensive support from initial target identification to preclinical validation, ensuring the highest quality and efficiency in developing promising therapeutic candidates. For more information or to discuss specific project needs, please contact us.

Reference

  1. Wittwer, N.L., et al. Antibody drug conjugates: hitting the mark in pancreatic cancer? J Exp Clin Cancer Res. 2023, 42: 280.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.